At Sunovion, we are advancing therapies to tackle some of the most challenging psychiatric and neurological disorders that impact the lives of millions of people worldwide. As a patient-centered company, we focus on improving the quality of life for those living with serious CNS conditions. Within a decade, we have introduced several new treatment options and will continue expanding our portfolio to enable better outcomes for those we serve. Innovation today, healthier tomorrows.
Our Mission, Vision & Values
Making a broad contribution to society
We strive to contribute to society through the innovative application of science and medicine for the betterment of health care worldwide.
Our People
and Culture
Bringing together diverse experiences, our people are the cornerstone of Sunovion and shape our culture while advancing our success. With their combined talent and dedication, they align, collaborate and win as one team.
Diversity & Inclusion
Sunovion is committed to embracing diversity and inclusion in everything we do. Our team brings a wide variety of experiences and approaches to work, allowing us to offer our patients the most innovative and effective solutions.
Social Responsibility
Because we believe in supporting the communities where we live and work, we partner with local organizations who share our passion. Far more than a commitment, we consider it our responsibility to make our world stronger and healthier.
Our History
Over the course of Sunovion's history, we have delivered clinical advances and new treatment options, and led advocacy and educational initiatives with cross-sector coalitions focused on the advancement of research, innovation and improvements in healthcare.
2020
- Health Canada approves Kynmobi™ (apomorphine hydrochloride) soluble film for the treatment of Parkinson’s disease OFF episodes.
- U.S. approves Kynmobi™ (apomorphine hydrochloride) sublingual film for the treatment of OFF episodes associated with Parkinson's disease (PD).
2019
- Sunovion Hands On! Annual Community Service Program contributes more than 30,000 employee volunteer hours in 439 projects in eight years to community organizations and relief efforts
2018
- Sunovion Hands On! Community Service Program contributes 25,000+ volunteer hours in 415+ projects in seven years
- Health Canada Approves of Aptiom® (eslicarbazepine acetate) as adjunctive therapy for the treatment of partial-onset seizures in adolescents above six years of age and as a monotherapy for adults with epilepsy
2017
- Receives FDA approval for Latuda® to treat adolescents with schizophrenia
2016
- Sunovion ranks as second-fastest growing pharmaceutical company*
- Receives Corporate Responsibility Award, United Way of Tri-County, 2016
- Complete acquisition of Cynapsus Therapeutics and its product candidate
2015
- Honoured with The JED Foundation Corporate Leadership Award for leadership in mental health
- Won SCRIP Award for Management Team of the Year
2014
- Health Canada approves Aptiom® as once-daily adjunctive treatment
2013
- FDA approves Latuda® as monotherapy and adjunctive therapy in adults with bipolar depression
- Receives FDA approval of Aptiom® (eslicarbazepine acetate) as adjunctive treatment of partial-onset seizures
2012
- Complete acquisition of Elevation Pharmaceuticals
- Launches annual Hands On! community service program to give back where employees live and work
- Health Canada approves Latuda® for schizophrenia in adults
2011
- Announces partnership with CARE Inc., an international humanitarian agency, to help improve the health and lives of those in need
2010
- Sunovion is established (October 2010) following the integration of Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc., former U.S. operations of Sunovion’s parent company Sumitomo Dainippon Pharma Co., Ltd.
- The FDA approves Latuda® (lurasidone HCl) for the treatment of adult patients with schizophrenia